Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare BATS:ARCM NASDAQ:CRTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARCMArrow Reserve Capital Management ETF$100.20-0.1%$100.34$99.99▼$101.74$46.15M0.01728 shs193 shsCRTXCortexyme$1.60+3.9%$1.68$1.78▼$40.66$48.24M1.4620,672 shs224,871 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARCMArrow Reserve Capital Management ETF0.00%-0.24%+0.01%+0.01%-0.13%CRTXCortexyme0.00%-1.84%-5.33%+53.85%+131.55%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARCMArrow Reserve Capital Management ETFN/AN/AN/AN/AN/AN/AN/AN/ACRTXCortexymeN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARCMArrow Reserve Capital Management ETF 0.00N/AN/AN/ACRTXCortexyme 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARCMArrow Reserve Capital Management ETFN/AN/AN/AN/AN/AN/ACRTXCortexymeN/AN/AN/AN/A$3.97 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARCMArrow Reserve Capital Management ETFN/AN/A0.00∞N/AN/AN/AN/AN/ACRTXCortexyme-$89.94M-$2.97N/AN/AN/AN/A-70.96%-63.53%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARCMArrow Reserve Capital Management ETF$4.634.62%N/AN/AN/ACRTXCortexymeN/AN/AN/AN/AN/ALatest CRTX, BRES, ARCM, and CMET DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date8/28/2025ARCMArrow Reserve Capital Management ETFmonthly$0.31863.82%8/29/20258/29/20259/3/20257/30/2025ARCMArrow Reserve Capital Management ETFmonthly$0.38104.56652017578905%7/31/20257/31/20258/5/20256/27/2025ARCMArrow Reserve Capital Management ETFmonthly$0.32963.94%6/30/20256/30/20257/7/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARCMArrow Reserve Capital Management ETFN/AN/AN/ACRTXCortexymeN/A9.929.92Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARCMArrow Reserve Capital Management ETFN/ACRTXCortexyme63.18%Insider OwnershipCompanyInsider OwnershipARCMArrow Reserve Capital Management ETFN/ACRTXCortexyme27.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARCMArrow Reserve Capital Management ETFN/A460,000N/ANot OptionableCRTXCortexyme5530.15 million21.74 millionNot OptionableCRTX, BRES, ARCM, and CMET HeadlinesRecent News About These CompaniesCortexyme (NASDAQ:CRTX) Stock Price Crosses Above 200 Day Moving Average - Here's What HappenedAugust 20, 2025 | marketbeat.comCortexyme (NASDAQ:CRTX) Shares Cross Above 200 Day Moving Average - Time to Sell?August 10, 2025 | marketbeat.comLilly files Alzheimer's drug donanemab as Cortexyme rival fails trialJanuary 26, 2025 | pharmaphorum.comPCrism Therapeutics Corp (CRTX)August 6, 2024 | fidelity.co.ukFCrism Thera Regulatory NewsAugust 4, 2024 | lse.co.ukAll the rumors are true: Syneos snapped up for $7.1B - FierceBiotechMay 12, 2023 | news.google.comNSiemens profits plummet 81% amid exit from cardiology robotics - FierceBiotechMay 11, 2023 | news.google.comNADC implements 'lower risk' R&D strategy with 17% layoffs ... - FierceBiotechMay 9, 2023 | news.google.comNFibroGen snags sole ADC asset from small biotech for $280M in ... - FierceBiotechMay 9, 2023 | news.google.comNIntuitive Surgical collects new prostate procedure clearances for its ... - FierceBiotechApril 28, 2023 | news.google.comNAntiva bags $53M in rare series E to finance quest for pivotal HPV ... - FierceBiotechApril 27, 2023 | news.google.comNAlzheimer's Disease Market in 7MM is expected to witness a major ... - Digital JournalApril 24, 2023 | news.google.comNParkinson's Disease Clinical Trials and Therapies 2023: Latest ... - Digital JournalApril 19, 2023 | news.google.comNAACR: Adela's multi-cancer blood test shows promise in detecting ... - FierceBiotechApril 18, 2023 | news.google.comNAACR: Kinnate ends cancer data wait but fails to captivate investors - FierceBiotechApril 18, 2023 | news.google.comNWith skin in the game, Satsuma's partner offers buyout to get ... - FierceBiotechApril 18, 2023 | news.google.comNCognito taps former BrainStorm president as medical chief - FierceBiotechApril 18, 2023 | news.google.comNTalaris lays off 95% of workforce after fruitless deal hunt - FierceBiotechApril 17, 2023 | news.google.comNBausch + Lomb exec to depart—Chutes & Ladders - FierceBiotechApril 14, 2023 | news.google.comNAKITA trial bites Guard as weak data force early end to phase 2 ... - FierceBiotechApril 14, 2023 | news.google.comNBioVentrix lassos $48.5M to take its ventricle-reshaping heart failure ... - FierceBiotechApril 14, 2023 | news.google.comNCRTX, BRES, ARCM, and CMET Company DescriptionsArrow Reserve Capital Management ETF BATS:ARCM$100.20 -0.12 (-0.11%) Closing price 08/29/2025 02:24 PM EasternExtended Trading$100.20 0.00 (0.00%) As of 08/29/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.The Arrow Reserve Capital Management ETF (ARCM) is an exchange-traded fund that mostly invests in investment grade fixed income. The fund is an actively managed fund that seeks to preserve capital and maximize income potential by investing in investment-grade, short-term debt securities. ARCM was launched on Mar 31, 2017 and is managed by ArrowShares.Cortexyme NASDAQ:CRTX$1.60 +0.06 (+3.90%) As of 08/29/2025Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Tencent Music Stock Outshines Spotify as China’s Music Giant With Shares Near Highs, Here's to Watch in Broadcom's Q3 Report Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
